Clinical Trials Browser

OTHER × brigatinib × 1 year × Clear all

NCT04374305 2026-05-06

INTUITT-NF2

Phase 2 Recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Phase 2 Active not recruiting

NSCLC

NCT04223596 2026-02-04

CUBIK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04925609 2025-12-05

Briga-PED

Phase 1/2 Recruiting

LymphoidPlasma cell

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT05200481 2025-11-17

MP-ALK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03707938 2025-11-03

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms